Navigation Links
ViroPharma Incorporated Reports Second Quarter 2009 Financial Results
Date:7/29/2009

me period in 2008. GAAP net loss per share for the six months ended June 30, 2009 was $0.56 per share, basic and diluted, compared to a GAAP net income per share of $0.56, basic, and $0.51, diluted, for the same period in 2008.

Non-GAAP adjusted net income in the three and six months ended June 30, 2009 was $34.5 million and $46.0 million, respectively, compared to $28.9 million and $51.0 million, respectively, for the same periods in 2008.

The primary drivers of the GAAP net loss in the six months ended June 30, 2009 was the impairment of goodwill for $65.1 million, offset by the gain on our repurchase of our senior convertible notes of $9.1 million. Contributing to this loss were launch costs for Cinryze, increased expenses relating to the development of our product pipeline, and the increase in amortization expense. GAAP net income decreased for the second quarter of 2009 as compared to 2008 due to a decrease in Vancocin sales, increased SG&A costs related to the launch of Cinryze, increased amortization and lower interest income, partially offset by Cinryze sales.

Effective January 1, 2009, the Company adopted Financial Accounting Standards Board's Staff Position No. APB 14-1, "Accounting for Convertible Debt Instruments That May Be Settled in Cash upon Conversion (Including Partial Cash Settlement)" ("FSP APB 14-1"), which changed the method of accounting for the Company's convertible notes. The Company revised its previously reported financial statements to apply this change in accounting to prior periods. Under this new accounting method, the Company's EPS and net (loss) income calculated in accordance with GAAP have been reduced as a result of recognizing incremental non-cash interest expense. In connection with adopting FSP APB 14-1, the Company recorded $1.7 million and $2.0 million of additional non-cash interest expense in the three months ended June 30, 2009 and 2008, respectively, and $3
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine news :

1. ViroPharma to Release 2009 Second Quarter Financial Results on July 29, 2009
2. ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
3. ViroPharma Announces Meeting of FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology on Bioequivalence Recommendations for Oral Vancomycin Hydrochloride Products
4. ViroPharma to Present at Two May Healthcare Conferences
5. ViroPharma to Present at the Cowen & Company 29th Annual Healthcare Conference
6. ViroPharma to Host Investor Teach-In Educational Symposium on Hereditary Angioedema
7. ViroPharma to Release 2008 Fourth Quarter and Full Year Financial Results on February 24, 2009
8. ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
9. ViroPharma to Present at the 27th Annual J.P. Morgan Healthcare Conference
10. ViroPharma Provides Update on Vancocin(R)
11. ViroPharma Submits Supplemental Biologics License Application for Cinryze(TM) to Treat Acute Attacks of Hereditary Angioedema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... 2014-- Colic affects about one in five infants in ... visits during the first several months after birth. Research ... showing promise; however, the April 1, 2014 issue of ... reported on a study, "Probiotics and Infant Colic," concluding ... for infant colic did not reduce crying ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on conservation ... today examining the current state of knowledge of the ... improved global surveillance strategies to combat the emergence of ... in West Africa that has claimed the lives of ... According to the World Health Organization (WHO), the ...
(Date:4/17/2014)... Arias, M.D., Ph.D., at The University of Texas Health ... superbug that caused a bloodstream infection in a Brazilian ... of The New England Journal of Medicine . ... of highly-resistant bacteria known as methicillin-resistant Staphylococcus aureus ... hospital and community-associated infections. The superbug has also acquired ...
(Date:4/17/2014)... April 17, 2014 Meaningful long-term survival is ... of the abdomen when treated with cytoreductive surgery ... a first-of-its-size analysis by physicians at Wake Forest ... the largest reported, single-center experience with cytoreductive surgery ... M.D., and analysis of 20 years, worth of ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2Health News:20 years of data shows treatment technique improvement for advanced abdominal cancer 2
... of the 1000 Genomes Project announced today that three ... have joined the international effort to build the most ... a tool for medical research. The new participants are: ... Biosystems, an Applera Corp. business, Foster City, Calif.; and ...
... Science,(Nasdaq: CSCX ), a global leader ... products, announced today,that it completed certification for ... Electronic Health Record (EHR)., (Logo: ... player in electronic health systems, with more,than ...
... children may have an impact on cardiovascular functioning equivalent ... to a research abstract that will be presented Wednesday ... Associated Professional Sleep Societies (APSS). , The study, authored ... Melbourne and Monash University, Melbourne, Victoria, Australia, focused on ...
... Ill. Widowed seniors are more likely to have disrupted ... event, according to a research abstract that will be presented ... the Associated Professional Sleep Societies (APSS). , The study, authored ... focused on 28 spousally bereaved seniors aged 60 years and ...
... insomnia delivered via the Internet can significantly improve insomnia ... be presented on Wednesday at SLEEP 2008, the 22nd ... , The study, authored by Lee Ritterband, PhD, of ... female) with an average age of 45 years. ...
... DaVita Inc., a leading,provider of kidney care ... disease (CKD), recently announced that Debbie Benner, MA, ... and Mary,Burgess, RD, Grant Program Manager for DaVita ... at the XIV International Congress on,Nutrition and Metabolism ...
Cached Medicine News:Health News:3 sequencing companies join 1000 Genomes Project 2Health News:3 sequencing companies join 1000 Genomes Project 3Health News:3 sequencing companies join 1000 Genomes Project 4Health News:3 sequencing companies join 1000 Genomes Project 5Health News:HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records 2Health News:HeartCentrix Informatics Solution from Cardiac Science Now Certified with Allscripts Electronic Health Records 3Health News:Primary snoring in children impacts cardiovascular functioning 2Health News:Primary snoring in children impacts cardiovascular functioning 3Health News:Disturbed sleep is prevalent in widowed seniors 2Health News:A self-help program delivered online can improve insomnia in adults 2Health News:DaVita Dietitians to Speak at the International Congress on Nutrition and Metabolism in Renal Disease in France 2
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... 2014  According to Millennium Research Group (MRG), the ... the United States and European ... expand moderately through 2022, with embolization particles representing ... interest in drug-eluting beads (DEBs) and radioembolization spheres ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
Breaking Medicine Technology:Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... 12, 2011 Varian Medical Systems, Inc. (NYSE: ... technology for treating cancer with radiotherapy, and privately-held Augmenix, ... under which Varian will make a $15 million minority ... hydrogel products to improve outcomes in radiation oncology.  The ...
... 12, 2011 Polaris Group (Polaris) today announced that ... Phase 3-ready pegylated arginine deiminase, ADI-PEG 20, during a ... China Standard Time in Taipei, Taiwan. Details ... ADI-PEG 20 in hepatocellular carcinoma (HCC) will be presented ...
Cached Medicine Technology:Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix 2Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix 3Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix 4Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 2Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan 3
... 10% Ash: 1.6% Gel ... Gel pH (1.5%): 5.0 7.0 Gel Point (1.5%): ... A (430 nm, 1.5%): 0.150 Resistance ... 25,000 Ohms EEO (-m r ): ...
... easy and economical generation of a hypoxic ... Chamber utilizes a surface-type seal where all ... by a stainless steel ring clamp for ... and semi-spherical top and bottom provide minimum ...
... of miniTHERM incubators is available, ensuring the ... for their specific requirements. miniTHERM incubators have ... and extremely space saving. Their size corresponds ... is possible to stack up to three ...
In microbiological laboratories and for in vitro fertilization, as well as in cancer research or tissue engineering, the Heraeus CO2 incubator BBD 6220 provides the best contamination protection and ...
Medicine Products: